Utah has cleared startup Nolla Health to let its artificial intelligence write prescriptions for acne creams under a supervised pilot, with physician oversight scaled back in stages, SiliconANGLE reported Monday. The company's founder described the arrangement as making Nolla an end-to-end AI doctor, a claim that rests on a narrow, tightly bounded set of treatments.

What Happened

Nolla said approval came from the Utah Office of Artificial Intelligence Policy and the Utah Division of Professional Licensing, with involvement from the Utah Medical Association and the American Academy of Dermatology. The pilot runs inside Utah's AI Learning Lab, a regulatory sandbox program.

Patients use the company's Nolla Derm app on iOS. After an intake screening, they describe their acne and upload a scan of their face. The AI then picks a treatment from a shortlist of topical medications that physicians have approved in advance. Patients can collect the prescription at a pharmacy or have it delivered, and daily skin scans feed monthly updates to the treatment plan, according to SiliconANGLE.

RelatedEight States Sue OpenAI as Iowa Seeks Court Halt on Testing of Advanced AI Models

The system cannot prescribe isotretinoin, the potent acne drug sold under brand names such as Accutane, or any oral medication. Cases outside its limits are routed to a licensed physician.

How Oversight Steps Down

The pilot is divided into three phases. In the first, two physicians must approve every prescription the AI generates, for at least 100 patients. In the second, the AI issues prescriptions directly to 500 patients and physicians review them after the fact. In the third, physicians review at least 10% of automated prescriptions each month.

That structure is the core of the experiment: it tests whether an AI can move from drafting prescriptions for doctors to issuing them on its own, with humans auditing a sample rather than signing off on each one. According to SiliconANGLE, the first stage must be completed without serious issues before the pilot can advance.

Why It Matters

In the U.S., prescribing has required a licensed clinician to authorize each order. Many telehealth services already use software to collect symptoms and photos, but a clinician makes the final call. Utah's pilot allows that final step to be automated for a defined set of low-risk drugs, and SiliconANGLE described Nolla as the first organization in the U.S. to get regulatory approval for an AI to issue initial prescriptions.

Utah created its sandbox to let companies test AI products under supervision with temporary relief from some state rules. The state has said participation in the program does not mean it endorses or certifies a product.

What Comes Next

Nolla's chief medical adviser, Zaid Fadul, told Inc. that the flu and uncomplicated urinary tract infections could be candidates for AI prescribing later, and that he expects AI to handle much routine health care within a decade. He also drew a line at higher-risk drugs, saying stimulants, opioids and benzodiazepines are not appropriate for automated prescribing.

What to Watch

The first test is whether Nolla clears phase one and the state allows it to begin prescribing without prior physician approval. Also worth watching are any published safety or error data from the pilot, how dermatology groups respond as oversight is reduced, and whether Utah or other states move to extend AI prescribing beyond topical acne treatment.